DARE Stock Analysis: Buy, Sell, or Hold?
DARE - Dare Bioscience, Inc. Common Stock
$1.84
0.29 (18.71%)
▲
5d:
+34.31%
30d:
+8.24%
90d:
-14.42%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When DARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: DARE is 10.8% above fair value ($1.66). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: DARE is 10.8% above fair value ($1.66). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$25.50
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$15.83
88.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DARE is currently trading at $1.84, which is considered extended relative to its 30-day fair value range of $1.41 to $1.66.
Technical Outlook: Technically, DARE is in a downtrend. The price is approaching resistance at $1.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 18.7% recently.
Market Sentiment: DARE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.33 (+566.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DARE is in a downtrend. The price is approaching resistance at $1.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 18.7% recently.
Market Sentiment: DARE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.33 (+566.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$1.41 -
$1.66
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+10.8% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+18.7%)
- BULLISH: Trading 566.7% below Wall St target ($10.33)
Fair Price Analysis
30-Day Fair Range
$1.41 -
$1.66
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.27
Resistance Level
$1.70
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.70
Wall Street Target
$10.33
(+566.7%)
Revenue Growth (YoY)
-94.6%
Share & Embed Analysis
Last updated: March 30, 2026 2:53 PM ET
Data refreshes hourly during market hours. Next update: 3:53 PM
Data refreshes hourly during market hours. Next update: 3:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DARE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 54 HOLD |
